Rivaroxaban reduces major bleeding in patients with venous thromboembolism

10/15/2013 | Healio (free registration)

Rivaroxaban worked as well as standard treatment for patients with symptomatic venous thromboembolism with a significantly lower rate of major bleeding events. About 4,100 patients each received rivaroxaban or standard therapy, and researchers reported 40 major bleeding incidents with rivaroxaban and 72 with standard treatment.

View Full Article in:

Healio (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC